Replies to post #223490 on Biotech Values

[DewDiligence]

Re: 2019 HCV market share

ABBV/ENTA’s 54% share of worldwide 4Q18 HCV sales (from ABBV or GILD) will hold roughly constant in 2019, according to the 2019 HCV sales guidance given by ABBV ($3.3B) and GILD ($2.7-2.9B).

[DewDiligence]

ABBV/(ENTA) had a 51%* worldwide share of 1Q19 combined ABBV/GILD HCV sales (#msg-148427663, #msg-148585355). The combined sales were flat QoQ (1605M/1600M).

*$815/$1,605M.